The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 25

PMID 35326719

Authors

Justyna Derebas

Kinga Panuciak

Mikolaj Margas

Joanna Zawitkowska

Monika Lejman

Affiliations

Soon will be listed here.

Abstract

One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.

Citing Articles

Pediatric B-cell Non-Hodgkin Lymphoma: The Impact of Therapy Response and Relapse on Outcome. A Single-center Analysis.

Stankiewicz J, Jablonska A, Treichel P, Demidowicz E, Styczynski J In Vivo. 2024; 38(6):2812-2819.

PMID: 39477426 PMC: 11535960. DOI: 10.21873/invivo.13761.

The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.

Anurogo D, Luthfiana D, Anripa N, Fauziah A, Soleha M, Rahmah L Adv Pharm Bull. 2024; 14(2):314-330.

PMID: 39206402 PMC: 11347730. DOI: 10.34172/apb.2024.034.

Distinguishing diffuse large B-cell lymphoma from Hodgkin's lymphoma in children using an enhanced computed tomography radiomics approach.

Si J, Wang H, Xie M, Yang Y, Wang F, Chen X Transl Pediatr. 2024; 13(5):716-726.

PMID: 38840678 PMC: 11148730. DOI: 10.21037/tp-23-586.

The Chemotherapeutic Potentials of Compounds Isolated from the Plant, Marine, Fungus, and Microorganism: Their Mechanism of Action and Prospects.

Shakya A, Naik R J Trop Med. 2022; 2022:5919453.

PMID: 36263439 PMC: 9576449. DOI: 10.1155/2022/5919453.

Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Sheikh I, Elgehiny A, Ragoonanan D, Mahadeo K, Nieto Y, Khazal S Cancers (Basel). 2022; 14(12).

PMID: 35740580 PMC: 9221186. DOI: 10.3390/cancers14122912.

References

Vaswani R, Gehling V, Dakin L, Cook A, Nasveschuk C, Duplessis M . Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2,.... J Med Chem. 2016; 59(21):9928-9941. PMC: 5451150. DOI: 10.1021/acs.jmedchem.6b01315. View

Hughes M, Landsburg D, Rubin D, Schuster S, Svoboda J, Gerson J . Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. Clin Lymphoma Myeloma Leuk. 2019; 19(12):791-798. DOI: 10.1016/j.clml.2019.09.612. View

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Rosen M . EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-92. PMC: 3681809. DOI: 10.1016/j.ccr.2013.04.011. View

Chen I, Sethy B, Liou J . Recent Update of HDAC Inhibitors in Lymphoma. Front Cell Dev Biol. 2020; 8:576391. PMC: 7494784. DOI: 10.3389/fcell.2020.576391. View

van Tilburg C, Milde T, Witt R, Ecker J, Hielscher T, Seitz A . Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clin Epigenetics. 2019; 11(1):188. PMC: 6902473. DOI: 10.1186/s13148-019-0775-1. View

Angi M, Kamath V, Yuvarani S, Meena J, Sitaram U, Manipadam M . The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. Hematol Oncol Stem Cell Ther. 2017; 10(3):126-134. DOI: 10.1016/j.hemonc.2017.03.002. View

Su I, Basavaraj A, Krutchinsky A, Hobert O, Ullrich A, Chait B . Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol. 2002; 4(2):124-31. DOI: 10.1038/ni876. View

Makena M, Nguyen T, Koneru B, Hindle A, Chen W, Verlekar D . Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies. Anticancer Drugs. 2020; 32(1):34-43. DOI: 10.1097/CAD.0000000000001008. View

Stephens D, Spurgeon S . Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015; 6(5):242-52. PMC: 4556969. DOI: 10.1177/2040620715592569. View

10.

Hata A, Engelman J, Faber A . The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 2015; 5(5):475-87. PMC: 4727530. DOI: 10.1158/2159-8290.CD-15-0011. View

11.

Kabir T, Chauhan A, Anthony L, Hildebrandt G . Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. Ochsner J. 2018; 18(4):370-376. PMC: 6292483. DOI: 10.31486/toj.18.0055. View

12.

Knight T, Luedtke D, Edwards H, Taub J, Ge Y . A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol. 2019; 162:250-261. DOI: 10.1016/j.bcp.2019.01.015. View

13.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

14.

Pytlik R, Polgarova K, Karolova J, Klener P . Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines (Basel). 2020; 8(4). PMC: 7768428. DOI: 10.3390/vaccines8040708. View

15.

Neelapu S, Adkins S, Ansell S, Brody J, Cairo M, Friedberg J . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020; 8(2). PMC: 7768967. DOI: 10.1136/jitc-2020-001235. View

16.

Dreyling M, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M . Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2015; 387(10020):770-8. DOI: 10.1016/S0140-6736(15)00667-4. View

17.

Minard-Colin V, Auperin A, Pillon M, Burke G, Barkauskas D, Wheatley K . Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020; 382(23):2207-2219. PMC: 7720281. DOI: 10.1056/NEJMoa1915315. View

18.

Jurczak W, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J . Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2017; 59(3):670-678. DOI: 10.1080/10428194.2017.1357175. View

19.

Burke G, Beishuizen A, Bhojwani D, Burkhardt B, Minard-Colin V, Norris R . Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Leukemia. 2020; 34(8):2271-2275. PMC: 7387295. DOI: 10.1038/s41375-020-0749-5. View

20.

Walter H, Rule S, Dyer M, Karlin L, Jones C, Cazin B . A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2015; 127(4):411-9. PMC: 4731845. DOI: 10.1182/blood-2015-08-664086. View